{"url_path":"/sec/tgtx/8-k/2026-06-03/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1001316/0001437749-26-019262-index.html","accession_number":"0001437749-26-019262","cik":"0001001316","ticker":"TGTX","issuer_name":"TG THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1001316/0001437749-26-019262-index.html","primary_entity_key":"0001001316","primary_entity_name":"TG THERAPEUTICS, INC."},"word_count":73,"has_tables":true,"body_markdown":"**Item 8.01.**\n\n**Other Events**\n\n \n\nOn June 3, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) in patients with relapsing forms of multiple sclerosis (RMS). A copy of the press release is being filed herewith as Exhibit 99.1 and incorporated into this Item by reference."}